Incyte(US:INCY)2025-02-10 13:08Financial Performance & Growth - Total revenues for 2024 grew by 15% year-over-year to $4.2 billion[10] - Jakafi net sales for FY 2024 were $2.792 billion, an increase of 8% year-over-year[23] - Opzelura net sales for FY 2024 were $508 million, representing a 50% increase year-over-year[31] - Q4 2024 Opzelura global net sales reached $162 million, a 48% increase year-over-year[31] Product Launches & Pipeline - Niktimvo U S launch is underway for 3L+ chronic Graft-Versus-Host Disease (GVHD)[16] - The company anticipates approximately $1 billion in incremental revenue by 2029 from near-term launches[20] - The company has more than 10 potential high impact launches by 2030[63] Financial Guidance - The company projects Jakafi net sales between $2.925 billion and $2.975 billion for FY 2025[24] - The company projects Opzelura net sales between $630 million and $670 million for FY 2025[31] R&D and Clinical Development - Povorcitinib is in Phase 3 development for Hidradenitis Suppurativa, Vitiligo, and Prurigo Nodularis, targeting patient populations of >300k, >1.5m, and >200k in the U S, respectively[50]